Table 1. Description of the participants.
| Patients | |||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Sub ID | Sex | Age | Symptom Onset | Duration (y) | UPDRS motor (Off) | UPDRS motor (On) | LED, mg/day | Experiment 1 | Experiment 2 |
| P01 | F | 72 | R | 3.5 | — | 11 | 300 | ✓ | 3 mo later |
| P02 | F | 73 | L | 4.5 | — | 18 | 480 | ✓ | |
| P03 | F | 72 | L | 4 | — | 38 | 300 | ✓ | |
| P04 | F | 70 | Bilateral | 0.8 | — | 13 | 500 | ✓ | 2.5 mo later |
| P05 | M | 72 | R | 4.6 | — | 15 | 167 | ✓ | |
| P06 | M | 69 | Bilateral | 1.6 | — | 8 | 195 | ✓ | |
| P07 | M | 79 | R | 2.2 | — | 8 | 500 | ✓ | 1 mo later |
| P08 | M | L | 7.6 | — | 5 | 738 | ✓ | ||
| P09 | M | 71 | R | 3.1 | — | 21 | 400 | ✓ | |
| P10 | F | 55 | R | 2.2 | — | 2 | 250 | ✓ | |
| P11 | F | 63 | R | 4.7 | — | 18 | 700 | ✓ | |
| P12 | M | 63 | L | 11.7 | 21 | 13 | 667 | ✓ | |
| P13 | M | 64 | R | 8.6 | 46 | 30 | 635 | ✓ | |
| P14 | M | 71 | Bilateral | 1.5 | 19 | 8 | 250 | ✓ | |
| P15 | F | 64 | R | 12.2 | 16 | 9 | 550 | ✓ | |
| P04 | F | 70 | Bilateral | 1.1 | 37 | 33 | 500 | ✓ | ✓ |
| P17 | F | 67 | L | 3.3 | 27 | 8 | 750 | ✓ | |
| P01 | F | 73 | R | 3.8 | 10 | 6 | 480 | ✓ | ✓ |
| P19 | F | 67 | R | 4.8 | 38 | 25 | 700 | ✓ | |
| P20 | M | 75 | L | 8.6 | 31 | 18 | 650 | ✓ | |
| P07 | M | 79 | R | 2.3 | 29 | 25 | 600 | ✓ | ✓ |
| Controls | |||||||||
|
| |||||||||
| Sub ID | Sex | Age | |||||||
|
| |||||||||
| C01 | M | 56 | |||||||
| C02 | F | 58 | |||||||
| C03 | F | 67 | |||||||
| C04 | F | 54 | |||||||
| C05 | M | 77 | |||||||
| C06 | M | 78 | |||||||
| C07 | M | 69 | |||||||
| C08 | F | 71 | |||||||
| C09 | M | 64 | |||||||
| C10 | M | 63 | |||||||
| C11 | F | 61 | |||||||
Parkinson's disease participants who were common in both experiments are shown in bold. M/F: male/females, R/L: right/left, LED: levodopa equivalent dose